| Nov 21 |
Pyxis stock craters 46% amid Phase 1 data, William Blair downgrade
|
| Nov 20 |
Pyxis Oncology plummets 38% on preliminary phase 1 data for cancer asset
|
| Nov 20 |
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
|
| Nov 12 |
Pyxis Oncology GAAP EPS of -$0.35 misses by $0.04
|
| Nov 12 |
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024
|
| Nov 11 |
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201
|
| Sep 13 |
Moment Of Truth Approaches For Pyxis Oncology
|
| Aug 29 |
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
|
| Aug 15 |
Pyxis Oncology GAAP EPS of -$0.29
|
| Aug 14 |
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
|
